These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17667926)

  • 1. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
    Hsieh AC; Moasser MM
    Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The upgraded role of HER3 and HER4 receptors in breast cancer.
    Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
    Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
    Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
    Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
    Campbell MR; Zhang H; Ziaee S; Ruiz-Saenz A; Gulizia N; Oeffinger J; Amin DN; Ahuja D; Moasser MM; Park CC
    Breast Cancer Res Treat; 2016 Feb; 155(3):431-40. PubMed ID: 26860947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
    Rosell R; Taron M; Reguart N; Isla D; Moran T
    Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of drugs targeting HER-family signalling in cancer.
    Montemurro F; Scaltriti M
    J Pathol; 2014 Jan; 232(2):219-29. PubMed ID: 24105684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
    J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER3/ErbB3, an emerging cancer therapeutic target.
    Zhang N; Chang Y; Rios A; An Z
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
    Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
    Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists.
    Johnston SR
    Int J Gynecol Cancer; 2006; 16 Suppl 2():543-8. PubMed ID: 17010069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
    Schaefer G; Shao L; Totpal K; Akita RW
    Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.
    Kol A; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Lamberts LE; Bensch F; de Vries EG; Schröder CP
    Pharmacol Ther; 2014 Jul; 143(1):1-11. PubMed ID: 24513440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
    Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
    APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA-205 regulates HER3 in human breast cancer.
    Iorio MV; Casalini P; Piovan C; Di Leva G; Merlo A; Triulzi T; Ménard S; Croce CM; Tagliabue E
    Cancer Res; 2009 Mar; 69(6):2195-200. PubMed ID: 19276373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.